We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.16 | -0.32% | 49.34 | 49.32 | 49.35 | 626 | 12:27:21 |
From May 2019 to May 2024
PARIS--French pharmaceutical company Sanofi SA (SAN.FR) and Belgium's UCB (UCB.BT) Tuesday agreed to jointly seek and develop new anti-inflammatory molecules to treat immune-mediated diseases in areas like gastroenterology and arthritis.
Sanofi and UCB will share costs and profits equally and UCB will be paid to for preclinical and clinical development that may surpass 100 million euros ($139 million).
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
